SG Americas Securities LLC Purchases 15,591 Shares of Krystal Biotech, Inc. $KRYS

SG Americas Securities LLC raised its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 469.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,909 shares of the company’s stock after purchasing an additional 15,591 shares during the period. SG Americas Securities LLC owned approximately 0.07% of Krystal Biotech worth $4,662,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in KRYS. Avoro Capital Advisors LLC boosted its holdings in shares of Krystal Biotech by 4.4% in the 3rd quarter. Avoro Capital Advisors LLC now owns 2,777,777 shares of the company’s stock valued at $490,361,000 after purchasing an additional 117,777 shares in the last quarter. State Street Corp lifted its position in shares of Krystal Biotech by 10.5% during the 2nd quarter. State Street Corp now owns 1,355,346 shares of the company’s stock worth $186,306,000 after buying an additional 128,639 shares during the last quarter. Soleus Capital Management L.P. lifted its position in shares of Krystal Biotech by 108.9% during the 2nd quarter. Soleus Capital Management L.P. now owns 922,958 shares of the company’s stock worth $126,870,000 after buying an additional 481,200 shares during the last quarter. Braidwell LP boosted its stake in Krystal Biotech by 81.6% in the second quarter. Braidwell LP now owns 727,811 shares of the company’s stock valued at $100,045,000 after buying an additional 327,067 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in Krystal Biotech by 5.5% in the third quarter. Dimensional Fund Advisors LP now owns 533,964 shares of the company’s stock valued at $94,261,000 after buying an additional 28,075 shares in the last quarter. 86.29% of the stock is currently owned by institutional investors.

Krystal Biotech Stock Up 0.2%

Shares of KRYS stock opened at $258.91 on Thursday. Krystal Biotech, Inc. has a twelve month low of $122.80 and a twelve month high of $298.30. The stock’s fifty day simple moving average is $265.71 and its 200 day simple moving average is $232.18. The firm has a market capitalization of $7.57 billion, a P/E ratio of 37.80 and a beta of 0.49.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Tuesday, February 17th. The company reported $1.70 EPS for the quarter, beating the consensus estimate of $1.62 by $0.08. The firm had revenue of $107.11 million during the quarter, compared to the consensus estimate of $105.30 million. Krystal Biotech had a return on equity of 18.69% and a net margin of 52.64%. As a group, equities research analysts expect that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Insider Buying and Selling at Krystal Biotech

In other Krystal Biotech news, CAO Kathryn Romano sold 12,500 shares of the business’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $272.14, for a total transaction of $3,401,750.00. Following the sale, the chief accounting officer directly owned 19,318 shares of the company’s stock, valued at $5,257,200.52. The trade was a 39.29% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Dino A. Rossi sold 18,950 shares of the company’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $261.41, for a total transaction of $4,953,719.50. Following the completion of the transaction, the director owned 78,691 shares of the company’s stock, valued at approximately $20,570,614.31. This trade represents a 19.41% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 129,164 shares of company stock worth $34,538,578 in the last 90 days. Corporate insiders own 13.70% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have commented on the company. Citigroup boosted their target price on Krystal Biotech from $336.00 to $371.00 and gave the stock a “buy” rating in a research note on Wednesday, February 18th. Guggenheim raised their price target on shares of Krystal Biotech from $224.00 to $284.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Wolfe Research began coverage on shares of Krystal Biotech in a report on Friday, March 27th. They set a “peer perform” rating on the stock. HC Wainwright reiterated a “buy” rating and set a $310.00 price objective (up from $240.00) on shares of Krystal Biotech in a research report on Friday, January 9th. Finally, Bank of America increased their price objective on shares of Krystal Biotech from $288.00 to $318.00 and gave the company a “buy” rating in a research note on Thursday, January 22nd. Eight investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, Krystal Biotech presently has a consensus rating of “Moderate Buy” and an average target price of $326.25.

Krystal Biotech Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.